Scandinavian Medical Solutions (SMSMED) Investor update summary

Updated financial guidance

• Revenue guidance for FY2024/25 has been revised to DKK 200-240 million, down from DKK 240-270 million.

• EBITDA guidance is now DKK 11-15 million, reduced from DKK 24-29 million.

Reasons for guidance adjustment

• Geopolitical instability is causing significant volatility in global markets.

• Potential import tariffs from Europe to the US have shortened the order book horizon.

• A growing proportion of long-term export customers are delaying purchases.

• Uncertainty regarding the USD exchange rate and customer purchasing power is impacting demand.